JD Health's Revenue Growth Likely Slowed in First Quarter -- Market Talk

Dow Jones04-14 12:01

0401 GMT - JD Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. (tracy.qu@wsj.com)

(END) Dow Jones Newswires

April 14, 2026 00:01 ET (04:01 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627990499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627990499","market":"fut","top_or_hot":-1,"title":"JD Health's Revenue Growth Likely Slowed in First Quarter -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. (tracy.qu@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 00:01 ET (04:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health's Revenue Growth Likely Slowed in First Quarter -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health's Revenue Growth Likely Slowed in First Quarter -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-14 12:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0401 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. (tracy.qu@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 00:01 ET (04:01 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGV7N243.SGD","symbol_name":"FSSA Global Emerging Markets Focus I Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627990499","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627990499","pubTimestamp":1776139260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0401 GMT - JD Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","BK1571":"互联网医疗","BK4531":"中概回港概念","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","06618":"京东健康","BK1591":"就地过年概念","BK4503":"景林资产持仓","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK1247":"药品零售","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4122":"互联网与直销零售","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1583":"高瓴概念","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4558":"双十一","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4505":"高瓴资本持仓","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK4504":"桥水持仓","BK1589":"北水核心资产","BK4579":"人工智能","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0051755006.USD":"摩根大通中国A (dist)","IE0008368742.USD":"首域中国增长基金I Acc","BK4588":"碎股","BK4614":"Manus概念股","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1142":"互联网与直销零售","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","SG9999002463.SGD":"LionGlobal China Growth SGD","BK4220":"综合零售","BK4551":"寇图资本持仓","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","KJD":"2倍做多JD ETF-KraneShares","BK4509":"腾讯概念","09618":"京东集团-SW","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK4524":"宅经济概念","BK1615":"港股-互联网"},"translate_title":"京东健康一季度营收增速可能放缓——市场热议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"KJD":0.6,"06618":1.96,"09618":0.6},"content_text":"0401 GMT - JD Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. (tracy.qu@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 00:01 ET (04:01 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627990499","isCrawlerRequest":true}